Trastuzumab (Herceptin, Roche/Genentech) in combination with chemotherapy remains the standard of care for the adjuvant treatment of HER2+ breast cancer, but there is still a question over which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback